Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "RMAT"

1869 News Found

India's healthcare policymakers call for digital health expansion and system strengthening
Policy | May 01, 2026

India's healthcare policymakers call for digital health expansion and system strengthening

Two-day long National Health Summit highlighted progress under the NHM and called for data-driven and SDG-aligned health system reforms


JP Nadda highlights India’s push for APIs, biologics and translational research
Policy | May 01, 2026

JP Nadda highlights India’s push for APIs, biologics and translational research

On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus


Gen Z split on AI as global study reveals rising tech optimism
Technology | April 30, 2026

Gen Z split on AI as global study reveals rising tech optimism

Health innovations are viewed more positively than food and agricultural technologies


CPHI & PMEC India 2026 expand to dual venues in Delhi NCR
News | April 30, 2026

CPHI & PMEC India 2026 expand to dual venues in Delhi NCR

CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart


Eli Lilly flags counterfeit Mounjaro products in Gurugram, backs regulatory action
Supply Chain | April 30, 2026

Eli Lilly flags counterfeit Mounjaro products in Gurugram, backs regulatory action

Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies


JP Nadda highlights India’s expanding healthcare ecosystem at PGIMER convocation
Policy | April 30, 2026

JP Nadda highlights India’s expanding healthcare ecosystem at PGIMER convocation

Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice


The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
interviews | April 28, 2026

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints


Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers
Biopharma | April 28, 2026

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026


Rheumatology Awareness Walkathon 2026 spotlights arthritis and autoimmune care
Healthcare | April 28, 2026

Rheumatology Awareness Walkathon 2026 spotlights arthritis and autoimmune care

Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living